We’ve recently updated our valuation analysis.

Sunshine Biopharma Valuation

Is SBFM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBFM?

Other financial metrics that can be useful for relative valuation.

SBFM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SBFM's PS Ratio compare to its peers?

SBFM PS Ratio vs Peers
The above table shows the PS ratio for SBFM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.1x
BIOC Biocept
0.2x7.4%US$15.6m
XBIO Xenetic Biosciences
5.2x10.3%US$7.7m
MRKR Marker Therapeutics
10.3x68.7%US$30.8m
LOGC LogicBio Therapeutics
0.9x-110.6%US$9.0m
SBFM Sunshine Biopharma
35.7xn/aUS$14.6m

Price-To-Sales vs Peers: SBFM is expensive based on its Price-To-Sales Ratio (35.7x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does SBFM's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: SBFM is expensive based on its Price-To-Sales Ratio (35.7x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is SBFM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBFM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SBFM's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SBFM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SBFM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SBFM's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies